These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Editorial: Standardization of drug names. Lewis JR JAMA; 1974 Jul; 229(5):559-60. PubMed ID: 4406902 [No Abstract] [Full Text] [Related]
3. When names make claims: ethical issues in medical device marketing. Bramstedt KA Ethics Med; 2004; 20(2):47-57. PubMed ID: 15468483 [No Abstract] [Full Text] [Related]
4. Standardization of drug names. Allan FM JAMA; 1974 Jul; 229(5):541-3. PubMed ID: 4406898 [No Abstract] [Full Text] [Related]
5. New names for drugs: what is USAN? Andrako J JAMA; 1977 May; 237(22):2413-4. PubMed ID: 576948 [No Abstract] [Full Text] [Related]
6. New drugs: the AMA and the FDA. Appel JZ Ann Allergy; 1966 Jul; 24(7):333-6. PubMed ID: 5941864 [No Abstract] [Full Text] [Related]
7. New drugs: the AMA and FDA roles. Appel JZ J Ark Med Soc; 1966 Jul; 63(2):67-9. PubMed ID: 4223555 [No Abstract] [Full Text] [Related]
8. Some thoughts on the generic equivalency debate. Berry FB Med Times; 1971 Sep; 99(9):199-201. PubMed ID: 5170858 [No Abstract] [Full Text] [Related]
9. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation. Daemmrich A Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740 [No Abstract] [Full Text] [Related]
10. USAN and FDA. Am J Pharm Sci Support Public Health; 1966; 138(5):172-4. PubMed ID: 5976320 [No Abstract] [Full Text] [Related]
11. Procedure for evaluation of new drugs. Weston JK J New Drugs; 1965; 5(5):294-6. PubMed ID: 5887954 [No Abstract] [Full Text] [Related]
12. Drugs, codes, standards, and other incompatible things in the dark. Chute CG MD Comput; 2001; 18(1):45-6. PubMed ID: 11236386 [No Abstract] [Full Text] [Related]
13. Two new efforts to inform patients about drugs launch a post-PPI era. Med World News; 1982 Sep; 23(20):8-9. PubMed ID: 11645760 [No Abstract] [Full Text] [Related]
14. Animal models in biomedical research: some epistemological worries. LaFollette H; Shanks N Public Aff Q; 1993 Apr; 7(2):113-30. PubMed ID: 11652915 [No Abstract] [Full Text] [Related]
15. Change in FDA definition of serious adverse drug event. Bader RL Am J Hosp Pharm; 1989 Jun; 46(6):1132. PubMed ID: 2750762 [No Abstract] [Full Text] [Related]
16. Worries about animal models in biomedical research: a response to LaFollette and Shanks. Willis LR; Hulsey MG Public Aff Q; 1994 Apr; 8(2):205-18. PubMed ID: 11652920 [No Abstract] [Full Text] [Related]
17. [Pharmacopeia and preparations for cutaneous application]. Esnault F; Etchegaray JP; Mallard C Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S40-5. PubMed ID: 17563714 [No Abstract] [Full Text] [Related]